For the quarter ending 2025-09-30, PHIO made $2,618K in revenue. -$2,392K in net income. Net profit margin of -91.37%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 1,181 | 1,074 | ||
| General and administrative | 1,324 | 1,235 | ||
| Total operating expenses | 2,505 | 2,309 | ||
| Operating loss | -2,505 | -2,309 | ||
| Interest income (expense), net | 113 | - | ||
| Total other income (expense), net | - | 143 | ||
| Other income (expense), net | 0 | - | ||
| Net loss | -2,392 | -2,166 | ||
| Net loss per common share, diluted | - | -0.45 | ||
| Weighted average number of common shares outstanding, diluted | - | 4,794,857 | ||
| Basic and diluted (in dollars per share) | -0.44 | -0.45 | ||
| Basic and diluted (in shares) | 5,468,584 | 4,794,857 | ||
Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp. (PHIO)